|
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 43, 2062-2071, December 2002 Molecular cloning and expression of rat liver bile acid CoA ligase
Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294 Published, JLR Papers in Press, September 16, 2002. DOI 10.1194/jlr.M200260-JLR200
1 To whom correspondence should be addressed. e-mail: charles.falany{at}ccc.uab.edu
Bile acid CoA ligase (BAL) is responsible for catalyzing the first step in the conjugation of bile acids with amino acids. Sequencing of putative rat liver BAL cDNAs identified a cDNA (rBAL-1) possessing a 51 nucleotide 5'-untranslated region, an open reading frame of 2,070 bases encoding a 690 aa protein with a molecular mass of 75,960 Da, and a 138 nucleotide 3'-nontranslated region followed by a poly(A) tail. Identity of the cDNA was established by: 1) the rBAL-1 open reading frame encoded peptides obtained by chemical sequencing of the purified rBAL protein; 2) expressed rBAL-1 protein comigrated with purified rBAL during SDS-polyacrylamide gel electrophoresis; and 3) rBAL-1 expressed in insect Sf9 cells had enzymatic properties that were comparable to the enzyme isolated from rat liver. Evidence for a relationship between fatty acid and bile acid metabolism is suggested by specific inhibition of rBAL-1 by cis-unsaturated fatty acids and its high homology to a human very long chain fatty acid CoA ligase. In summary, these results indicate that the cDNA for rat liver BAL has been isolated and expression of the rBAL cDNA in insect Sf9 cells results in a catalytically active enzyme capable of utilizing several different bile acids as substrates.
Abbreviations: BAL, bile acid CoA ligase; BAT, bile acid CoA:amino acid N-acyltransferase; CA, cholic acid; CDCA, chenodeoxycholic acid; CoA, coenzyme A; DCA, deoxycholic acid; FATP, fatty acid transport protein; LCA, lithocholic acid; THCA, trihydroxycoprostanoic acid Supplementary key words fatty acids coenzyme A CoA synthase bile acid amidation
Bile acids are one of a group of organic acids that are converted to N-acyl amino acid conjugates. They are the principal metabolites of cholesterol and have important detergent properties in the hepatobiliary system and in the lumen of the upper small intestine (1). The presence of the amino acid moiety lowers the pKa of the bile acid, thus preventing precipitation at the acid pH of the upper gut (2). Conjugation of bile acids with the amino acids glycine and taurine is a two-step process involving the successive action of the enzymes, bile acid CoA ligase (BAL), and bile acid CoA:amino acid N-acyltransferase (BAT). Our laboratories have previously purified BAT activity from human liver (3), and cloned a cDNA encoding hBAT from a human liver cDNA library (4). hBAT expressed in both bacterial and COS cells was demonstrated to utilize both glycine and taurine as substrates (4).
Although BAL activity was identified and enzymatically characterized over 40 years ago (5), purification of membrane-bound BAL activity has been a major challenge. Partial purification and characterization of BAL activity from guinea pig and porcine microsomes has been reported (6); however, the multiplicity and properties of the BAL proteins were not determined. Recently, our laboratory has described the purification of BAL activity from rat liver (7). Monoclonal anti-rBAL antibodies were generated and used to isolate rBAL so that partial amino acid sequence information could be obtained by chemical sequencing methods. The sequence of several peptides was utilized to design degenerate oligonucleotide probes for the cloning of rBAL cDNAs from a rat liver
Materials TRIzol reagent was purchased from Gibco BRL (Rockville, MD). Original TA Cloning and PCR optimizer kits were obtained from Invitrogen (Carlsbad, CA). The Wizard Plus Miniprep DNA purification system was from Promega (Madison, WI). The TaqStart Antibody was purchased from Clontech (Palo Alto, CA). Rat liver ZAP II cDNA library, the XL-1 MRF' cells, and SOLR cells were from Stratagene (La Jolla, CA). STAT-60 RNA isolation reagent was obtained from TEL-TEST (Friendswood, TX). First Strand Synthesis, Oligolabeling and ECL Plus western blot detection kits were purchased from Pharmacia Biotech (Arlington Heights, IL). QIAEX II gel purification kit was from Qiagen (Valencia, CA). Unlabeled chenodeoxycholic acid (CDCA), cholic acid (CA), lithocholic acid (LCA), deoxycholic acid (DCA), and coenzyme A (CoA) were from Sigma Chemical Co. (St. Louis, MO). Trihydroxycoprostanoic acid (THCA) and norcholic acid were gifts from Dr. Alan Hofmann (University of California, San Diego). [11,12-3H]CDCA was from NEN/Dupont (Wilmington, DE). [9,10-3H(N)]Oleic acid was from Perkin Elmer Life Sciences, Inc. (Boston, MA). All other reagents were of reagent grade and were from Fisher (Norcross, GA).
Molecular cloning of the 3'-end of rBAL
In order to generate a portion of the rBAL cDNA, rat liver total RNA was isolated using a TRIzol (Life Technologies) extraction procedure. Reverse-transcriptase polymerase chain reaction (RT-PCR) was performed using a First Strand Synthesis kit. A degenerate oligonucleotide primer was designed using the amino acid sequence determined from the CNBr cleaved fragment. This sequence, 5'-GCICCIGGIAARACIKKIGAYGG-3' [encodes APGKT(G,F)DG], was used in conjunction with oligo dT18 to perform PCR. Five microliters of the first strand synthesis reaction mix was added to each PCR reaction. Denaturation and extension cycles were performed at 94°C (1 min) and 72°C (2 min), respectively. For the first three cycles, the 1 min annealing temperature was 58°C. The annealing temperature was then lowered to 55°C for three cycles, to 53°C for three cycles, to 50°C for three cycles, and to 48°C for 21 cycles. The final extension reaction was carried out for 7 min at 72°C. Two major PCR products (
Isolation of the full-length rBAL cDNA
Approximately 300,000 independent clones from the
DNA sequence analysis
Northern blot analysis of RNA from different rat tissues
For use as a probe, the rBAL cDNA was isolated from the pBluescript plasmid by EcoRI digestion and purified from an agarose gel. The rBAL-1 cDNA was labeled with [32P]dCTP using an oligolabeling kit (Pharmacia) to a specific activity of
Immunoblot analysis of rBAL For immunoblot analysis of rBAL expression in rat tissues, microsomes were prepared from tissues of a young male Sprague Dawley rat and aliquots (80 µg) of the microsomal proteins were resolved by SDS-polyacrylamide gel electrophoresis. The resolved proteins were electrotransferred to a nitrocellulose membrane and the membrane was blocked with 5% non-fat milk. The membrane was then incubated with rabbit polyclonal anti-rBAL antiserum at a dilution of 1:4,000 for 1 h. Goat anti-rabbit IgG horseradish peroxidase conjugate was used as the secondary antibody and visualization of bound proteins was carried out using the Supersignal West Pico System (Pierce).
Expression of rBAL in Sf9 insect cells To isolate the baculovirus containing rBAL, Sf 9 cells growing in mid-log phase were seeded at a concentration of 9 x 105 cells/35-mm well in a 6-well plate in 2 ml of Sf-900 II SFM containing penicillin (50 U/ml) and streptomycin (50 µg/ml) and allowed to attach at 27°C for 1 h. For transfection, bacmid DNA, diluted in 100 µl Sf-900 II SFM without antibiotics, was gently mixed with CellFECTIN reagent diluted in 100 µl Sf-900 II SFM with antibiotics and incubated for 45 min at room temperature. The Sf 9 cells were washed once with 2 ml Sf-900 II SFM without antibiotics and overlaid with the DNA/CellFECTIN solution diluted with 800 µl Sf-900 II SFM. The cells were incubated at 27°C for 5 h, then the DNA/CellFECTIN solution was removed and replaced with fresh Sf-900 II SFM containing antibiotics. The cells were incubated at 27°C for 72 h and the baculovirus-containing supernatant fraction was removed and centrifuged at 500 g for 5 min to remove cells and debris. To prepare rBAL-containing microsomes, Sf 9 cells in mid-log phase in liquid culture were infected with the recombinant virus and incubated at 27°C for 72 h. The Sf 9 cells were then harvested by centrifugation at 500 g for 5 min. Cell pellets were resuspended in 0.1 M potassium phosphate buffer (pH 7.4), homogenized in a glass-Teflon homogenizer, and centrifuged at 10,000 g for 20 min at 4°C. The supernatant fraction was recovered and centrifuged at 100,000 g at 4°C for 1 h. The microsomal pellet was resuspended in 0.1 M potassium phosphate (pH 7.4) containing 1 mM DTT and 1 µg/ml PMSF. Protein concentrations were estimated using Bio-Rad dye reagent with gamma globulin as a standard. The His-tagged rBAL protein was further purified by Ni-NTA affinity chromatography.
rBAL assay To determine the Km of expressed rBAL for CDCA, the CDCA concentration in the assay was varied from 1 to 50 µM at constant CoA and MgCl2 concentrations of 50 µM and 2.5 mM, respectively. Sf 9 microsomes containing expressed rBAL were diluted with 0.1 M potassium phosphate to maintain CDC-CoA production between 5% and 10% of total CDCA in the reaction. In experiments to determine the ability of bile acids and fatty acids to inhibit rBAL activity, the nonradioactive bile acids and fatty acids were dissolved in isopropanol. The appropriate amount of bile acid or fatty acid was placed in the reaction tube and air-dried. The reaction mixture was added, thoroughly mixed, and incubated at 37°C for 2 min. The reactions were carried out and [3H]CDC-CoA isolated as described previously.
Product identification
Molecular characterization of rBAL cDNA The original partial rBAL cDNA was obtained by RT-PCR using rat liver total RNA as a template. A degenerate rBAL-selective primer was designed corresponding to part of the sequence of a peptide derived from proteolysis of pure rBAL. The degenerate rBAL primer and a dT18 oligomer were used as primers in the PCR reaction. Two major PCR products ( 450 bp and 300 bp) were generated. These DNA fragments were subcloned into pCR2.1 and sequenced. One fragment, 423 bp in length, encoded the four amino acids (QKLY) immediately following the sequence of the purified peptide used to design the degenerate oligonucleotide primer. The 423 nucleotide PCR product also encoded the sequence of a separate peptide derived from purified rBAL (Fig. 1)
. The 423bp cDNA fragment was then used as a probe to screen a Zap II Sprague Dawley rat liver cDNA library to isolate the full-length rBAL cDNA.
Three separate cDNA clones were isolated from screening the rat liver ZAP II cDNA library using high stringency conditions. Restriction enzyme analysis and DNA sequencing showed that the clones were closely related. The nucleotide sequence and translation of the longest clone, rBAL-1, is shown in Fig. 1. Clone rBAL-2 was identical to rBAL-1 except for being 42 bp shorter at the 5' end and truncated 9 bp prior to the polyadenylation site in rBAL-1. The third clone was identical to rBAL-1 except it lacked the initial methionine codon. The longest clone, rBAL-1, was therefore chosen for extensive sequence analysis and expression studies. The rBAL-1 cDNA contains 51 bp of 5'-nontranslated sequence and 138 bp of 3'-nontranslated sequence with a 101 bp poly(A) tail. A putative polyadenylation signal sequence, AATAAA, is located 17 bases upstream from the beginning of the poly(A) tail. rBAL-1 encodes a protein consisting of 690 amino acids with a predicted molecular mass of 76,260 Da (Fig. 1). The translation of rBAL-1 also contains the two polypeptides derived from sequencing of peptides obtained from purified rat liver rBAL protein. The one ambiguous amino acid (aa 607) in the peptide sequences is encoded as a phenylalanine in rBAL-1. Also, the peptide generated by CNBr digestion is positioned in the translation of rBAL-1 immediately after a methionine residue.
Northern blot analysis of rBAL expression in rat tissues
Immunoblot analysis of rBAL A rabbit polyclonal antibody was raised to a 463 amino acid fragment of the rBAL protein. The antibody was used in immunoblot analysis of rBAL in microsomes prepared from tissues of a young adult male Sprague Dawley rat. Figure 3 shows that immunoreactive rBAL was readily detectable in liver microsomes but not in microsomes prepared from spleen, kidney, lung, heart, or brain. A protein migrating with a slightly lower molecular mass than liver rBAL was detected in testis microsomes although no rBAL related message was observed in Northern blot analysis of testis RNA (Fig. 2). No immunoreactive rBAL was observed in rat liver cytosol.
Expression of rBAL-1 in Sf9 insect cells In order to characterize the enzymatic activity of rBAL, the rBAL-1 cDNA was expressed in Sf 9 cells using pFastBac baculoviral vectors. rBAL-1 was expressed in both native form and with an amino terminal histidine tag. Microsomes prepared from Sf 9 cells transfected with both the pFastBac1-rBAL and pFastBacHTb-rBAL vectors displayed significant amounts of rBAL activity with CDCA as a substrate (Fig. 4) . The microsomes containing the native rBAL protein consistently displayed higher specific activities than those with the His tagged rBAL. In contrast, control Sf 9 insect cell microsomes did not synthesize CDC-CoA. Analysis of the rBAL reaction by HPLC with UV detection and ESI-MS confirmed the formation of CDC-CoA. Analysis of the putative CDC-CoA product by ESI-MS showed that it had a [M+H]+ molecular ion of m/z 1143 in the positive ion mode and a [M-2H]2- molecular ion of m/z 569 in the negative ion mode. These ions matched those observed for synthetic CDC-CoA, confirming that expressed rBAL had generated CDC-CoA.
The effect of increasing CDCA concentrations on the activity of the two expressed forms of rBAL was also determined. rBAL activity was assayed at CDCA concentrations of 1, 2, 5, 10, 20, and 50 µM. Double reciprocal plots of enzyme velocity vs. CDCA concentration, generated apparent Km values of 32 µM for native rBAL expressed in Sf 9 microsomes and 64 µM for His-tagged rBAL. Wheeler et al. (7) have reported a Km of 18 µM for CDCA using purified rat liver BAL. These Km values are within the normal physiological bile acid concentrations that range from 20 to 100 µM (2).
Comparison of rBAL and acyl-CoA-synthetases
Inhibition of rBAL activity As shown in Fig. 5, rBAL displays significant homology with the CoA synthetase or FATP gene family (8) and at least one member of this family is capable of forming cholic acid CoA esters (19). Simion et al. (21) have reported that the bile acids DCA and CA acid were substrates for rBAL activity, and Wheeler (22) has also identified LCA and THCA as substrates of rBAL purified from rat liver. Vessey et al. (6) showed activity toward CDCA, CA, DCA, and LCA with purified guinea pig BAL. Therefore, the ability of several bile acids and fatty acids to inhibit the CDC-CoA ligase activity of baculovirus expressed rBAL was investigated. Table 1 shows that the CDC-CoA ligase activity of rBAL was strongly inhibited by LCA and moderately by THCA and DCA. CA was a relatively weak inhibitor of rBAL activity whereas norcholate did not show dose-dependent inhibition.
Steinberg et al. (19) have reported that human VLACS-H2, also known as FATP5, is capable of forming cholyl CoA. To determine whether fatty acids could bind and inhibit rBAL activity, several saturated and mono-unsaturated fatty acids were tested for their ability to inhibit CDC-CoA ligase activity. Table 2 shows that the unsaturated fatty acids, myristic acid (14:0), palmitic acid (16:0), and stearic acid (18:0) did not inhibit rBAL activity. However, the mono-unsaturated fatty acids, palmitoleic acid (16: 1 9C) and oleic acid (18:1 9C), displayed potent and dose-dependent inhibition of rBAL activity. In contrast, the trans-isomer of oleic acid, elaidic acid (18:1 9T), did not show significant inhibition, suggesting that the presence of the double bond in the 9 cis position is important for inhibition of rBAL activity.
Effects of detergents In order to evaluate the importance of the lipid environment of baculovirus expressed rBAL, we investigated whether two common nonionic detergents used in the solubilization of membrane-associated proteins would affect CDC-CoA ligase activity. rBAL and increasing concentrations of detergents were pre-incubated on ice for no more than 10 min before the determination of enzyme activity with CDCA. A range of microsome-detergent ratios were used to include those that were utilized for solubilization of rBAL for its purification from rat liver (7). Increasing Brij-58 concentrations adversely affected rBAL CDC-CoA activity with 20% inhibition of control activity observed at 0.01 mg Brij 58/mg protein (Fig. 6) . In contrast, Triton X-100 had no adverse affect on rBAL activity up to 0.05 mg detergent/mg protein. However, at 0.5 mg detergent/mg microsomal protein, Triton X-100 inhibited 95% of rBAL activity as compared with 86% inhibition by Brij-58.
This report describes the cloning and expression of BAL from rat liver, the enzyme specifically responsible for the first step in the conjugation of bile acids with amino acids. The rBAL-catalyzed formation of bile acid CoA thioesters activates the bile acids. This is necessary for their subsequent conjugation with glycine or taurine. Our laboratories have previously cloned and expressed bile acid CoA:amino acid N-acyltransferase (BAT), the enzyme responsible for the second step in the synthesis of bile acid amino acid conjugates from both human (4) and mouse liver (10). The cloning of rBAL will allow for the further investigation of the regulation, interaction, and function of these two important enzyme systems at the molecular level. The identity of the rBAL cDNA was confirmed by several approaches. The rBAL cDNA was isolated from a rat liver cDNA library using a cDNA probe generated by RT-PCR with rat liver total RNA as the template, according to the partial amino acid sequence of the previously purified rBAL enzyme (7). Two peptide sequences obtained from the analysis of the purified enzyme were identified in the translation of the rBAL cDNA confirming the relationship between the purified and cloned rBAL proteins. Also, high levels of CDC-CoA conjugation activity were detected in Sf 9 insect cells infected with a baculoviral vector containing the rBAL cDNA, whereas no CDC-CoA conjugation activity was detected in control Sf 9 cells. In addition, the amino acid sequence encoded by rBAL displays significant sequence similarity to fatty acid CoA synthetase/FATP proteins, indicating that rBAL is a member of this large gene family (23, 24). rBAL was previously purified from rat liver microsomes and the membrane dependence of rBAL for enzymatic activity was characterized (7). Initial attempts to express active full-length rBAL in E. coli resulted in expression in inclusion bodies. Therefore, to increase the likelihood of detecting rBAL activity, rBAL was expressed in Sf 9 insect cells using a baculoviral vector. rBAL was expressed both in its native form and with an amino terminal 6x His tag (rBAL6H). Sf 9 microsomes did not form detectable levels of CDC-CoA; however, microsomes from Sf 9 cells expressing either rBAL or rBAL6H displayed high levels of CDC-CoA conjugation activity. The apparent Km of the rBAL activity for CDCA (32 µM) expressed in Sf 9 cell microsomes was higher than that reported with the purified enzyme (18 µM)(7). The native enzyme purified from rat liver was solubilized with Brij-58, whereas the baculoviral expressed rBAL enzyme from Sf 9 cells was assayed as a Triton-X 100 solubilized microsomal preparation. The use of different detergents could account for the discrepancy in the Kms. Kelley and Vessey (25) have also reported that detergent mixed micelles interfere with kinetic analysis of guinea pig and porcine BAL activities. Therefore, the experiments in this report were carried out without the addition of detergents. Amino acids 176 of rBAL represent a highly lipophilic region that may have a role in the association of the protein with the endoplasmic reticulum membrane. The presence of the charged His tag at the amino end of the expressed protein decreased the level of expression of rBAL in Sf 9 microsomes, possibly by interfering with the membrane association of the protein. Also, the Km of rBAL6H activity for CDCA in microsomes was approximately twice that of the native enzyme, suggesting that the 6x His tag affected the active conformation and/or membrane association of the enzyme. Comparison of the sequence of rBAL with VLACS and related proteins from rat, mouse, and human demonstrated a high degree of similarity (Fig. 5). rBAL contains two highly conserved sequence motifs identified in the CoA synthetase gene family. The first is the AMP-binding domain (residues 294303) that is conserved among long- and very-long chain acyl-CoA synthetases (23). The second is a domain highly conserved in the VLACS/fatty acid transport protein gene family located at amino acids 546567 (24). These structural motifs increase the likelihood that rBAL is a member of the large fatty acid CoA synthetase/FATP gene family.
Expressed rBAL displayed high levels of bile acid conjugation activity; however, the translation of the rBAL cDNA has the most similarity to a mouse VLACS-related protein, highly expressed in liver (18). Enzymatic activity and substrates for this protein have not been reported. Another protein with a high level of similarity to rBAL is human VLACS-H2 (8). When expressed in COS-1 cells, hVLACS-H2 had low levels of activity toward several long chain fatty acids and was capable of forming cholyl CoA (19). Subsequently, hVLACS-H2 has been reported to form CoA esters of several primary and secondary bile acids as well as 3 hVLACS-H2 is selectively expressed in the microsomal fraction of human liver as would be expected of a bile acid CoA ligase (26). Polokoff et al. found fatty acid CoA ligase activity in microsomes isolated from all rat tissues; however, cholic acid CoA ligase activity was only found in liver microsomes suggesting two separate ligating enzymes (27). The possibility exists that human tissues possess multiple bile acid CoA ligases. Immunoreactive rBAL-related protein was detected in testis tissue, although the protein migrated with a different molecular mass during SDS-polyacrylamide gel electrophoresis. The identity of this protein is not known and is under investigation. Expression of VLACS-H2 in human testis tissue has not been reported. Differences in the amino acid sequences between the VLACS and rBAL are primarily in the N terminus domain. These differences could represent targeting or signal sequences to provide localization for the protein (24). rBAL, mouse VLACS-related protein, and VLACS-H2 lack the putative carboxyl terminal peroxisomal targeting signal (-LKL) identified in the mouse and rat VLACS proteins (14, 15). Steinberg et al. (19) also reported that VLACS-H2 is expressed in the endoplasmic reticulum rather than peroxisomes. Kase and Bjorkhen (28) reported that rBAT, the second enzyme in the bile acid amidation pathway, is localized in peroxisomes and is not highly expressed in cytosol. Only one BAT gene has been identified in human (10) and mouse (4) tissues, indicating that the bile acid CoA esters may have to migrate into peroxisomes for taurine or glycine conjugation before excretion into bile, unless a bile acid CoA ligase activity is identified in peroxisomes. The similarity between the VLACS proteins and rBAL indicates a possible overlap in function. Most of the various VLACS proteins have not been tested for their activity toward bile acids, and only VLACS-H2 has been reported to form bile acid CoA esters as well as long chain fatty acid CoA esters (19, 20). RBAL, which is capable of conjugating several bile acids (7), was inhibited by DCA, LCA, and CA, as well as by THCA, a C27 bile acid precursor that is known to form a CoA ester as a step in its conversion to C24 bile acids (29). Norcholic acid, a C23 bile acid, did not inhibit rBAL, consistent with the observation that it is not metabolized to a CoA ester in vivo (30). These results indicate that rBAL is capable of synthesizing a number of different bile acid CoA esters including both C24 and C27 conjugates.
Since VLACS-H2 was reported to form both long chain fatty acid and bile acid CoA esters (19, 20), fatty acids were examined as substrates for rBAL. To investigate whether rBAL can specifically bind and/or conjugate fatty acids, several fatty acids were tested as inhibitors of rBAL catalyzed CDCA-CoA synthesis activity. rBAL was not inhibited by high concentrations of C14 to C18 saturated fatty acids (Table 2), which suggests that many saturated fatty acids are not substrates for rBAL. In contrast, rBAL was strongly inhibited by palmitoleic (C16:1 Bile acid amidation is important for increasing the fat solubilization and absorption properties of bile acids. The cloning, expression, and characterization of both enzymes involved in bile acid amidation now allows for a more complete characterization of this process. Recently, patients presenting with fat-soluble vitamin deficiencies have been diagnosed with an inability to synthesize bile acid-amino acid conjugates (33). One possibility is that the loss of bile acid amidates in these patients is related to genetic defects in the expression of BAL or BAT activity. The cloning and characterization of BAL allows for a more thorough investigation of its role in the synthesis of bile acid and fatty acid CoA esters and the interactions between these two processes.
This research was supported in part by National Institutes of Health Grant DK46390. The rBAL sequence has been submitted to Genbank and has been assigned accession number AF242189. Norcholic acid and trihydroxycoprostanoic acid were kindly donated from Dr. Alan Hofmann (University of California, San Diego). The mass spectrometer was purchased by funds from a NIH/NCRR Shared Instrumentation Grant (S10RR06487) and from this institution. Operation of the UAB Comprehensive Cancer Center Mass Spectrometry Shared Facility has been supported in part by a NCI Core Research Support Grant to the UAB Comprehensive Cancer (P30 CA13148). Manuscript received July 3, 2002 and in revised form August 21, 2002.
This article has been cited by other articles:
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||